Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Facialist Katie Sobelman, better known as The Organic Esthetician, combines clean beauty with advanced beauty technology for ...

A biotech company is attempting to persuade Kansas legislators to modify the state’s controlled substances act in advance of ...

In this Healio Video Perspective from Telling It Like It Is, Cynthia Matossian, MD, FACS, shared pearls for ophthalmologists ...

Brain-computer interface startup Paradromics, a competitor to Elon Musk's Neuralink, is partnering with Saudi Arabia's Neom city-building project. As Bloomberg reports, the agreement will involve the ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.